With 4.9% CAGR, Global Antibiotics Market to Expand due to Rising Incidences of Chronic Disease Conditions

The global antibiotics market is expected to grow at growth rate of 4.9% to reach USD 59.6 billion by 2025. This comprehensive study reveals the market estimate numbers for different market segments. Along with that, the study covers qualitative insights, strategic benchmarking and thorough competitive landscaping in the report spreading over 102 pages.

Rising prevalence of infectious and chronic diseases drive the market growth to great extent. For example, according to the Epidemiology & Community Health Research, infectious diseases remain one of the most important causes of mortality and morbidity across the globe. This would, in turn, increase the demand for antibiotics, driving the market growth. In addition, rising approval of novel and effective antibiotics by government organizations drive the market growth. For example, in February 2015, AstraZeneca’s Ceftazidime-avibactam (Avycaz) was approved by the U.S. FDA for the treatment of complicated intra-abdominal (cIAI) infections. Similarly, in May 2014, the U.S. FDA approved Dalbavancin (Dalvance) for the treatment of acute bacterial skin and skin structure infections. All such factors, along with, rising geriatric population, advancement in technologies, and increasing demand for effective therapeutics are driving the industry demand. However, stringent regulatory policies, high research and development cost and growing concern over antibiotic overuse are likely to hamper the market growth over the future period.

To request free sample copy:
www.analystviewmarketinsights.com/request_sample/av178/

Key Takeaway:
- Of the different inhibitor types, cell wall synthesis segment accounted for the highest share of the total market. In 2017, the segment captured around 42% share and is projected to dominate the industry.
- RNA segment is projected to grow with the highest growth rate and is pegged to register a 6.2% CAGR in terms of value.
- Drug class is categorized into Cephalosporin, Fluoroquinolones, Macrolides, Carbapenems, Penicillin, Aminoglycosides, and other. Among which, cephalosporin is the highest revenue generating segment throughout the study period.
- Geographically, Asia Pacific region is accounted for the largest share. Whereas, regions such as North America and European countries are growing with the strong growth rate during the foreseeable future.
- Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG, and AstraZeneca are profiled in detail with the attributes such as company overview, financial performance, and key developments.
- Strategic collaborations are one of the most important strategies adopted by key players to expand their presence. For instance, in November 2017, Melinta Therapeutics, Inc. privately held novel broad-spectrum antibiotics developer, acquired the Medicines Company. This acquisition has helped Melinta to expand its product portfolio by addition Medicines’ marketed products such as Orbactiv (oritavancin), Vabomere (vaborbactam/meropenem), and Minocin IV (minocycline).

Browse full report with in-depth ToC on “Antibiotics Market, By Inhibitor Types (Protein Synthesis, Cell Wall, DNA, and RNA), By Drug Class (Fluoroquinolones, Cephalosporin, Penicillin, Macrolides, Carbapenems, Aminoglycosides) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at
www.analystviewmarketinsights.com/report-highlight-antibiotics-market/

The scope of this report covers the market by its major segments, as follows:

Market, by Service:
Regulatory Writing & Publishing
Regulatory Consulting
Clinical Trial & Product Registration
Legal Representation

Market, by Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Rest of the World

Market, by Country
U.S.
Canada
Germany
France
India
China

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles of companies):
Novartis AG
Johnson & Johnson
Pfizer, Inc.
GlaxoSmithKline, Inc.
Bayer AG
AstraZeneca plc

Key benefits of the report:
• The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
• A thorough analysis of relevant statistical data to estimate the market paradigms
• Exceptional understanding of region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
• Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Find out more by getting in touch: https://www.analystviewmarketinsights.com/get-in-touch/

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: sales@analystviewmarketinsights.com
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)
Web: www.analystviewmarketinsights.com

This release was published on openPR.